The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., HCK, BTK, LYN, BLK, FRK) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating diseases (e.g., proliferative diseases) in a subject in need thereof).
本公开提供了化合物的结构式(I),以及其药学上可接受的盐、溶剂合物、
水合物、多型体、共晶体、互变异构体、立体异构体、同位素标记衍
生物和前药。所提供的化合物可能是激酶(例如HCK、BTK、LYN、BLK、FRK)
抑制剂。还提供了包括所提供的化合物的药物组合物和试剂盒。进一步提供了使用所提供的化合物、药物组合物和试剂盒的方法(例如,用于治疗患有疾病(例如增殖性疾病)的患者)。